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PURPOSE. To quantify retinal nerve fiber layer thickness
(RNFLT) and macular thickness (MT) in patients exhibiting
vigabatrin-attributed visual field loss (VAVFL) and to determine
the efficacy of these measures as markers of the retinal damage
associated with vigabatrin.
METHODS. This was a prospective cross-sectional observational
study involving five groups: Group I, 13 patients exhibiting
VAVFL; Group II, 8 patients exposed to vigabatrin but with
normal fields; Group III, 14 patients receiving carbamazepine
monotherapy; Group IV, 20 normal individuals; and Group V,
7 patients receiving sodium valproate monotherapy. At one of
two visits, the right eye of each participant underwent two
digital imaging modalities: ocular coherence tomography
(OCT; StratusOCT; Carl Zeiss Meditec, Dublin, CA) and scan-
ning laser ophthalmoscopy (SLO; Heidelberg Retinal Tomo-
graph; Heidelberg Engineering GmbH, Heidelberg, Germany).
At the other visit, participants underwent three-zone, age-
corrected suprathreshold perimetry of the whole field and
threshold perimetry of the central field (Humphrey Field Ana-
lyzer 750; Carl Zeiss Meditec). The order of the visits was
randomized.
RESULTS. The group mean RNFLT in Group I was attenuated
relative to that of the remaining groups (all P  0.001). At
100% specificity, based on the 95% confidence limits derived
from Group IV, OCT exhibited 100% sensitivity and SLO 77%
sensitivity for an attenuated RNFLT in patients with VAVFL. All
participants manifested an MT within the normal range derived
from Group IV.
CONCLUSIONS. OCT of the RNFL can efficiently identify vigaba-
trin-induced damage and will be useful for adults and children
unable to perform perimetry and when the perimetric out-
come is equivocal. (Invest Ophthalmol Vis Sci. 2006;47:
917–924) DOI:10.1167/iovs.05-0854
Vigabatrin, the first of the novel anti-convulsants, is used inapproximately 85 countries outside the United States, as
adjunctive therapy for the treatment of epilepsy of partial
onset1–3 and as monotherapy for infantile spasms,4,5 particu-
larly those secondary to tuberous sclerosis.6 Vigabatrin is a
selective and irreversible inhibitor of the enzyme -aminobu-
tyric acid (GABA)-transaminase, which catalyzes the inactiva-
tion of GABA, a major inhibitory neurotransmitter in the retina
and cortex.7 The resultant anticonvulsant effect of vigabatrin is
thought to occur from the increase in concentration of presyn-
aptic GABA.
Vigabatrin is associated with a bilateral constriction of the
visual field.8–15 The estimated prevalence of vigabatrin-attrib-
uted visual field loss ranges from 14%16 to 92%17 but is gener-
ally considered to be in the region of 40% to 50%.12,13,18,19
Patients with vigabatrin-attributed field loss exhibit normal
visual acuity and are usually asymptomatic of the field loss
unless the defect encroaches well within the central
field.8,10–15 Approximately 20% of adults with epilepsy, and
particularly those exposed to vigabatrin, are unable to appre-
ciate the requirements of perimetry due to the cognitive re-
quirements for, and the subjective nature of, the task.20 In
many others, the results of perimetry can often be inconclusive
and frequently require one or more confirmatory repeat exam-
inations, even though the results of the subsequent tests can
remain equivocal.
Vigabatrin-attributed field loss can exist in the presence of
an apparently normal optic nerve head and retina12,21 or can
be associated with optic nerve head pallor11,15,22,23 with or
without a variety of accompanying subtle retinal abnormalities
including surface wrinkling retinopathy9,23 peripheral retinal
arterial narrowing9,15; irregular sheen, or abnormal pigmenta-
tion, at the macula9; peripheral pigmentary disturbance14,15;
and thinning of either the peripapillary13 or peripheral22,23
retinal nerve fiber layer. The inconclusive and subtle nature of
any coexisting optic nerve head and retinal abnormalities pre-
cludes the use of fundal examination by ophthalmoscopy as an
indicator of vigabatrin-attributed field loss.
The postmortem examination of the retina of a patient with
vigabatrin-attributed field loss has indicated loss of rod and
cone nuclei and extensive loss of retinal ganglion cells and
their axons.24 An attenuated retinal nerve fiber layer has been
described in one patient with vigabatrin-attributed visual field
loss, detected by optical coherence tomography (OCT),25 and
in another by confocal scanning laser ophthalmoscopy
(SLO).26 However, although likely to be of particular use in the
assessment of vigabatrin-induced damage, digital imaging tech-
nology of the ocular fundus has yet to be applied in a system-
atic manner to patients receiving antiepileptic drugs.
The overall aim of the present study, therefore, was to
investigate the potential of retinal imaging to indicate vigaba-
trin-attributed field loss. The specific aims were to quantify, in
patients with vigabatrin-attributed field loss and in patients
exposed to vigabatrin but with normal fields, retinal nerve fiber
layer and macular thicknesses by OCT, and the retinal nerve
fiber layer thickness by SLO, thereby determining whether any
of these measures could be used as a marker for vigabatrin-
attributed retinal damage. The two different imaging modalities
were evaluated to determine which technique, if any, pos-
sessed the better sensitivity and specificity. If structural mark-
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ers could be determined, it is possible that such changes might
occur before the visual field loss became established.
METHODS
The study was of a cross-sectional prospective observational design.
Cohort
The cohort comprised five groups of consecutively presenting patients
and normal individuals, aged 18 years or older, who had volunteered to
take part in the study after invitation by letter. Group I comprised 13
patients with epilepsy of various etiologies who had been or were
currently, exposed to vigabatrin and manifested vigabatrin-attributed
field loss. Group II comprised eight patients with epilepsy who had
been or were currently, exposed to vigabatrin and manifested normal
visual fields. Two additional patients exposed to vigabatrin exhibited
equivocal visual fields and therefore could not be categorized in either
Group I or II. Group III comprised 14 patients with epilepsy who had
never been exposed to vigabatrin and who, at the time of the study,
were receiving carbamazapine monotherapy. Carbamazepine is an
anti-epileptic drug; the primary mechanism of action is believed to be
the blockade of voltage-dependent sodium channels. The patients in
Group III therefore served as the control for the effects of GABA
modulation. Group IV comprised 20 clinically normal individuals who
did not have epilepsy and who had not been exposed to antiepileptic
drugs. These individuals served as a basis for the creation of appropri-
ate confidence limits for normality for the results from the retinal
imaging. Group V comprised seven patients with epilepsy who were
included in the study after the data for the remaining four groups had
been analyzed, and it had become apparent that patients in Groups I
and II had frequently been treated with the antiepileptic drug sodium
valproate before, or as combination therapy with, vigabatrin. Valproate
has a mild GABAergic action believed to result from inhibition of
GABA-transaminase and of succinic semialdehyde dehydrogenase and
from the stimulation of benzymeglutamic acid dehydrogenase which
synthesizes GABA. The patients in Group V had been treated with
valproate monotherapy and served, as a post hoc control, for those
patients in Group I who had been treated with valproate.
All patients were recruited from the Welsh Epilepsy Unit, Univer-
sity Hospital of Wales, Cardiff, and the normal individuals from the
University Hospital of Wales and from the Eye Clinic, Cardiff School of
Optometry and Vision Sciences, Cardiff University. The participants
were matched as closely as possible in age within and between the
respective groups. As far as possible, patients were matched for age at
onset, and duration, of epilepsy.
All participants had undergone ocular examination and conformed
in each eye to rigid inclusion criteria, including a distance refractive
error less than or equal to 5 diopters mean sphere and less than 2.5
diopters cylinder; open angles, and clear ocular media; no optic nerve
head or fundal abnormalities characteristic of known disease; no pre-
vious ocular surgery or trauma; no history of diabetes mellitus and no
family history of glaucoma. All participants manifested a visual acuity of
20/30 or better in each eye and an intraocular pressure of 21 mm Hg
or less.
The participants attended two further visits. At one visit, they
underwent visual field examination of the right eye. At the other, they
underwent retinal imaging in the same eye. The order of the imaging
and perimetry visits was randomized between individuals.
Perimetry
The visual field examination was performed with the Humphrey Visual
Field Analyzer 750 (Carl Zeiss Meditec, Dublin, CA). Three-zone, age-
corrected suprathreshold perimetry was undertaken with the Full Field
135 Point Screening Program, followed by threshold perimetry under-
taken with Program 30-2 and the FASTPAC strategy. The appropriate
refraction, corrected for the viewing distance of the perimeter bowl,
was used during the examination of the central field. No correction
was used for the examination beyond 30° from fixation. Patients were
given frequent rest periods throughout each perimetric examination
and a break of 15 to 30 minutes between examinations.
If either of the visual field examinations for any given patient were
inconclusive, the corresponding examination was repeated at a subse-
quent visit. One patient with an unequivocal normal field derived by
the Full Field 135 Point Screening Program was unable to complete
Program 30-2.
Each participant in the five groups exhibited stable fixation for
each perimetric examination, as indicated by the response to the gaze
tracker and the responses to the fixation loss catch trials. The incorrect
responses to the false-positive catch trials were also within the normal
range (30%) for all participants. The incorrect responses to the
false-negative catch trials were within the normal range (30%) for all
individuals in Groups II through V. In Group I, two patients exhibited
incorrect responses beyond the normal range for the Full Field 135
Point Screening Program, one participant for Program 30-2, and one for
both programs.
Imaging
The imaging visit consisted of retinal imaging with OCT (StratusOCT,
Carl Zeiss Meditec) and SLO with the Heidelberg Retina Tomograph II
(HRT; Heidelberg Engineering, Dossenheim, Germany).
For OCT, each participant first underwent the Fast Optic Disc scan,
centered on the optic disc, from which the vertical diameter of the
optic nerve head was obtained. The participants then underwent three
separate 360° circular scans, centered on the optic disc, using the
Proportional Circle scan incorporating a scan radius that corresponded
to the vertical diameter of the optic nerve head, thereby accounting for
between-subject differences in the size of the optic nerve head. The
macula was then separately imaged using the Macular Thickness Map
scan and the Fast Macular Thickness Map scan. The two types of
Macular Thickness Map scan were undertaken to determine whether
the Fast Macular Thickness Map scan exhibited equivalent sensitivity
and specificity relative to the longer acquisition time and increased
resolution of the Macular Thickness Map scan.
The contralateral eye was occluded and participants fixated on the
internal fixation target. The z-offset and polarization were optimized
before each Proportionate Circle and Macular Thickness Map scan was
acquired. All scans exhibited the requirements of a signal-to-noise ratio
greater than 25 dB and at least 90% good-quality A-scans. The images
were then each analyzed by StratusOCT software version 3.0.
For SLO, the corneal radius was determined before imaging with a
keratometer (Bausch & Lomb, Rochester, NY) to correct the images for
ocular magnification. Three separate scans of the optic nerve head, and
the immediate surrounding retina, were automatically obtained by the
HRT software which then computed the mean of the three scans to
form the output topographic image and the SD of the mean to ascertain
the quality of the resulting mean image. The field size was 15°  15°.
The participants fixated on the internal fixation target. The SD of the
mean was 10 m in 9 of the 55 participants, between 11 and 20 m
in 36, between 21 and 30 m in 9 participants, and 57 m in the
remaining participant in Group III. The contour line was drawn by a
senior ophthalmologist (IAC) trained to fellowship standard in glau-
coma and highly experienced in optic nerve head assessment and in
the drawing of the contour line with the HRT, who was masked to the
purpose and design of the study. The images were then analyzed by
HRT software version 1.6.
The order of the imaging modality was randomized between
the participants. The right eye of each participant was dilated with
0.5% tropicamide before imaging, to ensure a minimum pupil diameter
of 5 mm.
Analysis
The primary analysis was undertaken on the results from the patients
in Groups I through IV. After completion of the data collection for the
groups, the visual field results from each participant were evaluated by
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one of the authors (JMW), who was aware of the categorization of
participants into one of four potential groups but was masked to all the
remaining clinical information including the therapeutic history and
the results of the retinal imaging. No patients in Group III and no
individuals in Group IV manifested visual field loss. The post hoc
inclusion of the patients in Group V meant that the evaluator was
aware that these patients were receiving valproate; however, he was
masked to the results of the retinal imaging. All seven patients exhib-
ited normal fields.
For OCT, the retinal nerve fiber layer thickness of individual par-
ticipants in each group was compared with the lower 95th confidence
limit calculated from the individuals in Group IV and derived from the
group mean  t  SD where t is the appropriate percentile of the t
distribution with n  1 degrees of freedom. Separate analysis of
covariance (ANCOVA) was undertaken for Groups I to IV on the
average thickness for the complete 360° scan and for the four sectors,
superior, inferior, nasal, and temporal. The mean of the three separate
Proportional Circle scans for each participant was used for each anal-
ysis. For each of the two data sets, group was considered as a between-
subjects factor and age as the covariate. Suitable linear contrasts were
then used to compare the average thickness between pairs of groups,
corrected for any age differences. Inferential analysis was not under-
taken for the thickness in 30° segments due to the likelihood of Type
I errors arising from vast number of multiple comparisons.
Results for individual participants for both types of OCT Macular
Thickness Map scan were compared with the corresponding normal
limits calculated from the individuals in Group IV. Separate ANCOVAs
were undertaken for both types of scan, using the weighted average
thickness according to the standard weighting function.27 Linear con-
trasts were also used to compare the weighted average thickness
between pairs of groups, corrected for any age differences.
For HRT, the results for the individuals in each group were com-
pared with the lower 95th confidence limits calculated from the
normal individuals in Group IV. Separate ANCOVAs were undertaken
for the mean nerve fiber layer thickness at the radial extremity along
the entire contour line and for the mean nerve fiber layer thickness for
each of six sectors: nasal, temporal, superior nasal, superior temporal,
inferior nasal, and inferior temporal. Linear contrasts compared the
mean overall thickness, and also the mean thickness for each of six
sectors, between pairs of groups, corrected for any age differences.
The research complied with the tenets of the Declaration of Hel-
sinki. All individuals were provided with verbal and written informa-
tion concerning the nature of the study and gave written informed
consent after explanation of the nature and possible consequences of
the study, in accordance with the guidelines of the Local Research and
Ethics Committee.
RESULTS
The respective biographical data (group mean and SD) for each
of the five groups are listed in Table 1. At the time of the study,
six patients in Group I and one patient in Group II were being
treated with vigabatrin. The mean duration of vigabatrin ther-
apy was greater in Group I than in Group II (P  0.049), but
the mean cumulative dose of vigabatrin was similar between
the two groups (P  0.337).
In the patients in Group III, the mean period of mono-
therapy with carbamazepine was 1.0  1.2 years (SD) with a
minimum period of 6 months. Five of the 14 patients had been
on monotherapy throughout their clinical care. Two patients
had each been treated with sodium valproate for 4 years and
one patient with the antiepileptic drug phenytoin for 6 years.
The remainder had received a variety of non-GABAergic anti-
epileptic drugs that had been withdrawn due to intolerance or
ineffectiveness after short periods ranging from 12 days to 5
months. The mean duration of carbamazepine therapy was
6.1  6.4 years, and the mean cumulative dose was 1.19  1.3
kg (SD).
The age of the patients was similar between the four groups
(P  0.847). The apparent difference in the duration of epi-
lepsy between the patients in Groups I and II and those in
Group III did not reach statistical significance (P  0.430).
Six of the seven patients in Group V had received valproate
monotherapy throughout their clinical care. The seventh pa-
tient had received the antiepileptic drug lamotrigine as add-on
therapy for approximately 5 months, 6 years previously. The
mean duration of valproate therapy was 7.9  3.6 years, and
the mean cumulative dose was 3.44  2.2 kg.
Optical Coherence Tomography
The average retinal nerve fiber layer thickness for the complete
360° scan for each participant as a function of group is given in
Figure 1. All patients with vigabatrin-attributed visual field loss
exhibited a nerve fiber layer thickness beyond the lower 95%
confidence limit for normality (i.e., 100% sensitivity at 100%
specificity) Three of the eight patients exposed to vigabatrin
and manifesting normal visual fields exhibited an apparently
abnormal nerve fiber layer thickness.
Average retinal nerve fiber layer thickness for the complete
360° scan varied across Groups I through IV (P  0.001; Table
2). The mean average thickness in Group I, 64.8 m, was
attenuated relative to that of Group II, 97.1 m (P  0.001);
Group III, 101.5 m (P 0.001); and Group IV, 110.6 m (P
0.001). Given the limited size of the study sample and given the
tendency for an increased likelihood of a Type I statistical error
resulting from the multiple comparisons of means, there was
some evidence to suggest that the mean average thickness in
Group II was attenuated relative to that of Group IV (P 
0.022). However, this latter outcome was influenced by the
two patients in Group II with an average thickness lying out-
side the 95% confidence limits. The trend in the average thick-
ness between Groups I and II was repeated for each of the
superior, inferior, and nasal sectors (Table 2).
The average nerve fiber layer thickness for the complete
360° scan in patients exposed to vigabatrin as a function of the
Mean Sensitivity derived with Program 30-2 is shown in Figure
2 and as a function of duration of therapy with vigabatrin and
of a cumulative dose of vigabatrin in Figure 3.
TABLE 1. The Summary Biographical Data for Each of the Five Groups
Group
Proportion Male:
Female
Age (SD)
(y)
Duration of
Epilepsy (SD)
(ys)
Duration of Vigabatrin
Therapy (SD)
(kg)
Cumulative Dose
of Vigabatrin (SD)
(kg)
I 7:6 42.9 (8.9) 27.3 (10.8) 10.1 (1.9) 7.8 (2.7)
II 8:0 40.1 (10.8) 25.9 (16.8) 7.3 (4.2) 6.1 (4.5)
III 3:11 41.2 (8.8) 19.5 (15.3) Nil Nil
IV 5:15 39.7 (12.3) Nil Nil Nil
V 4:3 35.0 (11.2) 21.3 (14.8) Nil Nil
Data are the group mean  SD.
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All patients, regardless of group, exhibited a weighted mean
macular thickness within the 95% confidence limits of normal-
ity for either type of scan derived from the participants in
Group IV. The group means for the weighted mean macular
thickness in the Fast Macular Thickness Map scan and in the
Macular Thickness Scan did not differ across Groups I through
IV for either type of scan (P  0.086) and (P  0.086),
respectively.
Of the two patients exposed to vigabatrin who exhibited
equivocal visual fields, one manifested an abnormal nerve fiber
layer thickness and a normal macular thickness. The other
manifested normal nerve fiber layer and macular thicknesses.
Scanning Laser Ophthalmoscopy
Ten of the 13 patients with vigabatrin-attributed visual field
loss exhibited a mean nerve fiber layer thickness derived by
SLO beyond the 95% confidence limits for normality (i.e.,
76.9% sensitivity at 100% specificity; Fig. 4). Two of the eight
patients exposed to vigabatrin and manifesting normal visual
fields exhibited an apparently abnormal nerve fiber layer thick-
ness.
The mean nerve fiber layer thickness derived by SLO (Table
3) varied across Groups I to IV (P  0.001). The mean Mean
Thickness in Group I, 0.126  0.05 (SD) was attenuated rela-
tive to that of Group II, 0.210  0.10 mm (P  0.034);
Group III, 0.290  0.10 (P  0.001); and Group IV, 0.260 
0.06 mm (P  0.001). The trend in the overall thickness
between Groups I and II for each of the six sectors was less
convincing and not as profound as the sector analysis for OCT
(Table 2).
Of the two patients exposed to vigabatrin who exhibited
equivocal visual fields, one manifested an abnormal and the
other a normal nerve fiber layer thickness.
DISCUSSION
The results provide evidence of an attenuated retinal nerve
fiber layer thickness in patients with vigabatrin-attributed vi-
sual field loss. Moreover, the sensitivity and specificity of the
digital imaging techniques used in the study, particularly that
of OCT, combined with the objective nature and relatively
short chair time, suggest that the technique may be considered
in clinical practice for the assessment of vigabatrin-attributed
damage. In addition, the technique is also advocated for the
evaluation of potential structural damage to the retina by ex-
FIGURE 1. The average retinal nerve fiber layer thickness (in micrometers) derived by OCT, for the
complete 360° scan in each of the participants in each of the five groups. Shaded diamonds: patients
exhibiting vigabatrin-attributed visual field loss; open circles: patients exposed to vigabatrin but with
normal visual fields; shaded squares: patients receiving carbamazapine monotherapy; open triangles:
normal individuals; and filled diamonds: patients receiving sodium valproate monotherapy. The lower
95th percentile for normality is illustrated by the dashed line. Two patients exposed to vigabatrin
(indicated by the filled triangles) each exhibited equivocal visual fields.
TABLE 2. The Probabilities for the Comparison of the Mean Average RNFL Thickness with the Mean
Sector Average RNFL Thickness for the Complete 360° Scan
Group Comparison 360° Superior Inferior Nasal Temporal
I v II P  0.001 P  0.001 P  0.001 P  0.001 P  0.016
I v III P  0.001 P  0.001 P  0.001 P  0.001 NS
I v IV P  0.001 P  0.001 P  0.001 P  0.001 P  0.001
II v III NS NS NS NS NS
II v IV P  0.022 P  0.039 P  0.044 P  0.025 NS
III v IV NS NS NS NS NS
Data were derived by OCT in each of Groups I through IV.
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isting GABAergic antiepileptic drugs and for those in Phase III
studies.
The visual electrophysiology associated with vigabatrin is
complex but suggests a retinal rather than a cortical origin for
vigabatrin-attributed field loss. Vigabatrin is associated with a
reduced Arden Index of the electrooculogram (EOG)10,28,29
and abnormalities of the electroretinogram (ERG) including
reduced cone b-wave,9,30 a decreased amplitude of the 30-Hz
flicker response,20,23 and abnormalities in photopic and
scotopic oscillatory potentials.9,11,13,30,31 Separation of the
electrophysiological effects due to vigabatrin therapy from
those associated with vigabatrin-attributed damage, implicates
an abnormal cone function in association with the field loss.20
However, although the latencies of the photopic a-wave and of
the 30 Hz flicker a-wave and the 30 Hz flicker a-b amplitude
yield encouraging sensitivities for the detection of at least
severe vigabatrin-attributed field loss, the accompanying spec-
ificities are not sufficiently high to justify implementation of
the technique.20 Wide-field multifocal electroretinography may
yield better outcomes in this regard.32 The presence of func-
tional abnormality at the fovea, such as reduced contrast
sensitivity33,34 and abnormal color vision13,32,34,35 in patients
exposed to vigabatrin is also equivocal and, therefore, measure-
ment of these functions cannot be used to indicate vigabatrin-
attributed field loss.
All patients in Groups I and II had received a variety of
antiepileptic drugs encompassing the complete range of avail-
able therapies. However, eight of the 13 patients with vigaba-
trin-attributed visual field loss had been treated with sodium
valproate before therapy with vigabatrin and four of these
eight had received combination therapy of valproate and viga-
batrin. The mean duration of therapy with valproate in this
group was 10.0  6.2 years. Six of the eight patients had been
treated with valproate for nine years or more. In contrast, only
two of the eight patients in Group II had received valproate:
one for almost 5 years before therapy with vigabatrin and the
other for 16 years of which 11 years included combination
therapy with vigabatrin. One patient in Group II received
valproate after withdrawal of vigabatrin. It is not possible to
attribute, unequivocally, the attenuation of the nerve fiber
layer to vigabatrin. Nevertheless, the evidence for a purely
vigabatrin etiology is persuasive. The evidence from the study
is three fold. Firstly, all patients in Group I exhibited field loss
unequivocally characteristic of vigabatrin irrespective of expo-
sure to valproate. Second, the two patients with long-term
exposure to valproate in Group II both exhibited normal fields.
Finally, all seven patients in Group V receiving valproate mono-
therapy exhibited a nerve fiber layer thickness well within the
normal range by both OCT (group mean 110.0  7.7 m [SD])
and SLO (group mean 0.273  0.06 mm [SD]). The evidence
from the literature is also convincing. Characteristic vigabatrin-
attributed visual field loss has been observed with vigabatrin
monotherapy12 and, in the most authoritative study of val-
proate monotherapy and visual function, involving 32 patients
treated for a mean duration of 6 years and using a daily dose
between 1000 and 2000 mg, visual acuity, color vision, central
field, and scotopic and photopic ERGs were all normal.36 The
drug history of the patients in Groups I and II is believed to
reflect the local idiosyncrasy of the prescribing practice in the
Welsh Epilepsy Unit during the early to mid 1990s when
valproate was prescribed as the drug of first choice for all types
FIGURE 3. The average retinal nerve fiber layer thickness (in microme-
ters) for the complete 360° scan derived by OCT as a function of (top)
duration of therapy (years) with vigabatrin and (bottom) cumulative
dose of vigabatrin (kilograms) for the patients with vigabatrin-attrib-
uted visual field loss (Group I; diamonds) and for the patients exposed
to vigabatrin but with normal fields (Group II; circles). Note that the
cumulative dose could not be determined accurately in one patient in
Group II, and the value has been omitted from Figure 3 (bottom).
FIGURE 2. The average retinal nerve fiber layer thickness (in microme-
ters) for the complete 360° scan derived by OCT against Mean Sensi-
tivity (in decibels) derived with Program 30-2 in the patients with
vigabatrin-attributed visual field loss (Group I; diamonds) and for the
patients exposed to vigabatrin but with normal fields (Group II; cir-
cles). Note that one patient with unequivocally normal fields did not
complete Program 30-2 and therefore cannot be included in the figure.
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of epilepsy and vigabatrin as the first choice add-on therapy for
partial refractory epilepsy. Nevertheless, vigabatrin-attributed
damage may be greater for combination therapy with valproate
compared to combination therapy with carbamazepine.37 It
may well be that such an effect is more profound with the long
durations of valproate, and/or vigabatrin, encountered in the
patients in Group I.
The time to occurrence of an attenuated retinal nerve fiber
layer thickness resulting from vigabatrin therapy is unknown as
is the extent of any further attenuation over time. Three pa-
tients exposed to vigabatrin but with normal fields manifested
an abnormal average nerve fiber layer thickness for the com-
plete 360° scan by OCT. Similarly, two patients exposed to
vigabatrin but with normal fields manifested an abnormal mean
nerve fiber layer thickness by SLO. One of the patients exhib-
ited abnormality by both techniques. These findings suggest
that digital ocular imaging may be a more sensitive indicator
than perimetry for vigabatrin-attributed damage. This is not
surprising, given that retinal nerve fiber layer defects occur
frequently in glaucoma, for example, before the emergence of
a visual field defect.38
The two patients who received carbamazepine therapy and
manifested an abnormal average retinal nerve fiber layer thick-
ness by OCT did not exhibit any unusual clinical characteris-
tics. Their retinal nerve fiber layer thickness was normal by
SLO. The finding cannot be explained.
Despite the frequent characteristic binasal appearance of
vigabatrin-attributed visual field loss within the central field out
to 30° eccentricity, the corresponding selectively greater atten-
uation in the temporal retinal nerve fiber layer thickness by
OCT was not present in the four-sector analysis or in the
graphic representation of the 30° sector analysis. Similarly, no
differences were found in the HRT results. Potential functional
and structural correlation is likely to be confounded by several
factors, including the lack of axial resolution of the segmental
analysis contained on the respective OCT and HRT printouts,
the lack of knowledge concerning the precise configuration
between the given visual field stimulus location and the point
of entry into the optic nerve head by the corresponding gan-
glion cell axons,39 and the between-individual variability in this
correspondence.39
The HRT results for the retinal nerve fiber layer thickness
exhibited proportionately greater between-subject variability
than the OCT in Groups III and IV. The greater variability is
likely to stem from the reliance of the technique on the des-
ignation of the contour line by the clinician.
FIGURE 4. The mean retinal nerve fiber layer thickness (in millimeters) derived by SLO for each of the
participants in each of the five groups. Shaded diamonds: patients exhibiting vigabatrin-attributed visual
field loss; open circles: patients exposed to vigabatrin but with normal visual fields; shaded squares:
patients receiving carbamazapine monotherapy; open triangles: normal individuals; and filled diamonds:
patients receiving sodium valproate monotherapy. The lower 95th percentile for normality is illustrated by
the dashed line. Two patients exposed to vigabatrin (indicated by the filled triangles) exhibited equivocal
visual fields.
TABLE 3. The Probability Values for the Comparison of the Mean Overall RNFL Thickness with the Mean Sector RNFL Thickness Derived
by SLO
Group Comparison 360° Superior Nasal Superior Temporal Nasal Temporal Inferior Nasal Inferior Temporal
I vs. II P  0.034 NS NS P  0.031 P  0.026 NS P  0.032
I vs. III P  0.001 P  0.001 P  0.001 P  0.001 NS P  0.003 P  0.004
I vs. IV P  0.001 P  0.001 P  0.001 P  0.001 P  0.046 P  0.023 P  0.021
II vs. III NS P  0.028 NS P  0.019 NS NS NS
II vs. IV NS NS NS NS NS NS NS
III vs. IV NS NS NS NS NS NS NS
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The mean average nerve fiber layer thickness measured by
OCT exhibits an apparent floor effect at approximately 47 m.
However, it should be noted that the papillomacular bundle of
ganglion cell fibers is seemingly unaffected by vigabatrin23 and
thus will contribute to the average value for the nerve fiber
layer thickness. The minimum individual recorded thickness
for the thinnest sector, the nasal sector was 30 m.
The retinal nerve fiber layer thickness decreases with in-
creasing eccentricity from the optic nerve head.40–42 Two
concepts exist for the selection of a circular scan for OCT. The
first advocates a fixed diameter circular scan of 3.46 mm. This
diameter is large enough to prevent any overlap with the optic
nerve head in nearly all eyes and combines measurement of a
reasonably thick area of the RNFL with optimum reproducibil-
ity.40 The normative database contained within the StratusOCT
is based on such a diameter. However, the use of a fixed
diameter scan is highly dependent on the axial length and, to
a lesser extent, on the refractive power of the eye being
imaged and does not account for variation in optic disc size
within the population. A fixed-diameter scan therefore mea-
sures the nerve fiber layer thickness closer to the optic disc
border in larger discs than in smaller ones.42 The second
approach, adopted in the present study, utilizes a scan radius
based on an increment of the vertical disc diameter; in this
instance, unity. Such an approach overcomes the variation in
the size of the optic nerve head. The choice of the increment
is arbitrary. A scan radius based on an increment of unity
yielded a mean normal average nerve fiber layer thickness of
110.6 m. A scan radius closer to the optic nerve head (i.e., an
increment of less than unity) would have yielded a thicker
measure of the retinal nerve fiber layer which would have
enabled a greater measurement range. The use of a scan radius
based on an increment of the vertical disc diameter would be
appropriate for the follow-up of children and adolescents.
The normal macular thickness in all patients in Groups I and
II indicates that, within the resolution of the OCT, vigabatrin
was not associated with a disturbance of the macula. There was
no evidence of epiretinal membrane formation within the
patients in Groups I or II. SLO was not used to evaluate the
macula because, at the time of the study, the software permit-
ting evaluation of the macula was not commercially available.
In summary, digital imaging of the retina by two different
optical techniques, OCT and SLO, yielded an attenuated retinal
nerve fiber layer thickness for patients with vigabatrin-attrib-
uted visual field loss. Macular thickness was normal by OCT.
Assessment of retinal nerve fiber layer thickness, particularly
by OCT, is a clinically viable indicator of vigabatrin-attributed
damage and may be considered as an adjunct to the assessment
of all adult patients exposed to vigabatrin, particularly the
learning disabled and those in whom the visual field result is
equivocal. Wherever possible, it should also be considered for
children exposed to vigabatrin.
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